BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115. [PMID: 21428766 DOI: 10.1056/nejmoa1010949] [Cited by in Crossref: 514] [Cited by in F6Publishing: 549] [Article Influence: 46.7] [Reference Citation Analysis]
Number Citing Articles
1 Thatcher R, Gregory N, Cheung WY, Dunseath GJ, Parsons SN, Goodwin M, Luzio SD. Brief lifestyle interventions for prediabetes in primary care: a service evaluation. BMC Prim Care 2022;23:45. [DOI: 10.1186/s12875-022-01658-2] [Reference Citation Analysis]
2 Piťhová P. The role of pioglitazon in modern treatment of type 2 diabetes. Med Pro Praxi 2022;19:279-283. [DOI: 10.36290/med.2022.043] [Reference Citation Analysis]
3 Wareham NJ. Personalised prevention of type 2 diabetes. Diabetologia 2022. [PMID: 35916901 DOI: 10.1007/s00125-022-05774-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Blonde L, Umpierrez GE, Reddy SS, Mcgill JB, Berga SL, Bush M, Chandrasekaran S, Defronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fisher M. Glitazones and Glitazars. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch12] [Reference Citation Analysis]
6 Collier JJ, Burke SJ. Special Issue: Emerging Paradigms in Insulin Resistance. Biomedicines 2022;10:1471. [DOI: 10.3390/biomedicines10071471] [Reference Citation Analysis]
7 Liu T, Li H, Conley YP, Primack BA, Wang J, Lo W, Li C. A Genome-Wide Association Study of Prediabetes Status Change. Front Endocrinol 2022;13:881633. [DOI: 10.3389/fendo.2022.881633] [Reference Citation Analysis]
8 Takahara M, Shiraiwa T, Maeno Y, Yamamoto K, Shiraiwa Y, Yoshida Y, Nishioka N, Katakami N, Shimomura I. Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01064-w] [Reference Citation Analysis]
9 Shan Y, Cole SA, Haack K, Melton PE, Best LG, Bizon C, Kobes S, Köroğlu Ç, Baier LJ, Hanson RL, Sanna S, Li Y, Franceschini N. Association of protein function-altering variants with cardiometabolic traits: the strong heart study. Sci Rep 2022;12:9317. [PMID: 35665752 DOI: 10.1038/s41598-022-12866-2] [Reference Citation Analysis]
10 Ryang S, Kim SS, Bae JC, Han JM, Kwon SK, Kim YI, Nam-Goong IS, Kim ES, Kim MK, Lee CW, Yoo S, Koh G, Kwon MJ, Park JH, Kim IJ. A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study. Diabetes Obes Metab 2022. [PMID: 35581902 DOI: 10.1111/dom.14766] [Reference Citation Analysis]
11 Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-62. [PMID: 35569886 DOI: 10.1016/j.eprac.2022.03.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 25.0] [Reference Citation Analysis]
12 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
13 Rosolová H. Prediabetes. Vnitr Lek 2022;68:82-84. [DOI: 10.36290/vnl.2022.016] [Reference Citation Analysis]
14 Pang B, Zhang YY, Hu HJ, Sun Y, Cao AM, Lu CQ, Zhang WH, Ni Q. Prevention of Diabetes in Overweight/Obese Adults through Traditional Chinese Patent Medicine: Study Protocol for a Prospective Cohort Study. Evid Based Complement Alternat Med 2021;2021:6006802. [PMID: 35265141 DOI: 10.1155/2021/6006802] [Reference Citation Analysis]
15 Davidson MB. Historical Review of the Diagnosis of Prediabetes/Intermediate Hyperglycemia: Case for the International Criteria. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109219] [Reference Citation Analysis]
16 Luo Y, Wang H, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Paul SK. A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. J Diabetes Res 2022;2022:2971382. [PMID: 35036447 DOI: 10.1155/2022/2971382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Francois ME, Oetsch KM. Prediabetes: Challenges, Novel Solutions, and Future Directions. EMJ. [DOI: 10.33590/emj/21-00148] [Reference Citation Analysis]
18 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S39-45. [PMID: 34964876 DOI: 10.2337/dc22-S003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
19 Yaturu S. Prediabetes Progression to Diabetes among Veterans with Post Traumatic Stress Disorder. JDM 2022;12:28-34. [DOI: 10.4236/jdm.2022.121004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cheng AYY. SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes. The Lancet Diabetes & Endocrinology 2022;10:2-3. [DOI: 10.1016/s2213-8587(21)00310-7] [Reference Citation Analysis]
21 Kawa LB. Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea. JDM 2022;12:87-97. [DOI: 10.4236/jdm.2022.122009] [Reference Citation Analysis]
22 Kohlenberg J, Vella A. “Is Prediabetes a Risk Factor or Is It a Disease?”. Clinical Dilemmas in Diabetes 2021. [DOI: 10.1002/9781119603207.ch1] [Reference Citation Analysis]
23 Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. Annu Rev Public Health 2021;42:59-77. [PMID: 33355476 DOI: 10.1146/annurev-publhealth-090419-102644] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 24.0] [Reference Citation Analysis]
24 Liu Y, Guo H, Wang Q, Chen J, Xuan Y, Xu J, Liu Y, Sun K, Gao Q, Sun Z, Wang B. Short-term effects of lifestyle intervention in the reversion to normoglycemia in people with prediabetes. Prim Care Diabetes 2021:S1751-9918(21)00225-4. [PMID: 34930688 DOI: 10.1016/j.pcd.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Guha MK. PREDIABETES – RISKS AND APPROACH FOR MANAGEMENT. PIJR 2021. [DOI: 10.36106/paripex/3500371] [Reference Citation Analysis]
26 Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2021;:108101. [PMID: 34922811 DOI: 10.1016/j.jdiacomp.2021.108101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Brinton EA. Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications? Arterioscler Thromb Vasc Biol 2021;41:2798-801. [PMID: 34705475 DOI: 10.1161/ATVBAHA.121.316893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Al-Thani MH, Al-Mutawa KA, Alyafei SA, Ijaz MA, Khalifa SAH, Kokku SB, Mishra ACM, Poovelil BV, Soussi MB, Toumi AA, Dargham SR, Awad SF, Abu-Raddad LJ. Characterizing epidemiology of prediabetes, diabetes, and hypertension in Qataris: A cross-sectional study. PLoS One 2021;16:e0259152. [PMID: 34699571 DOI: 10.1371/journal.pone.0259152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kharechkina ES, Nikiforova AB, Belosludtsev KN, Rokitskaya TI, Antonenko YN, Kruglov AG. Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition. Pharmaceuticals (Basel) 2021;14:1045. [PMID: 34681269 DOI: 10.3390/ph14101045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021;161:1657-69. [PMID: 34602251 DOI: 10.1053/j.gastro.2021.07.049] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 48.0] [Reference Citation Analysis]
31 Thiruvengadam S, Peter PR. Management of type 2 diabetes without insulin: An update for the PCP. Dis Mon 2021;:101290. [PMID: 34563347 DOI: 10.1016/j.disamonth.2021.101290] [Reference Citation Analysis]
32 Morgunova TB, Glinkina IV, Fadeev VV. Prediabetes: challenges and opportunities. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-12-220-227] [Reference Citation Analysis]
33 Greabu M, Badoiu SC, Stanescu-Spinu II, Miricescu D, Totan AR, Badoiu SE, Costagliola M, Jinga V. Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review. Int J Mol Sci 2021;22:9782. [PMID: 34575946 DOI: 10.3390/ijms22189782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Collier JJ, Batdorf HM, Merrifield KL, Martin TM, White U, Ravussin E, Burk DH, Cooley CR, Karlstad MD, Burke SJ. Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans. Biomedicines 2021;9:1189. [PMID: 34572374 DOI: 10.3390/biomedicines9091189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 B. Stentz F. Hyperglycemia- and Hyperlipidemia-Induced Inflammation and Oxidative Stress through Human T Lymphocytes and Human Aortic Endothelial Cells (HAEC). Sugar Intake - Risks and Benefits and the Global Diabetes Epidemic 2021. [DOI: 10.5772/intechopen.94427] [Reference Citation Analysis]
36 Zhang M, Huang L, Yang J, Xu W, Su H, Cao J, Wang Q, Pu J, Qian K. Ultra-Fast Label-Free Serum Metabolic Diagnosis of Coronary Heart Disease via a Deep Stabilizer. Adv Sci (Weinh) 2021;8:e2101333. [PMID: 34323397 DOI: 10.1002/advs.202101333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
37 Jonas DE, Crotty K, Yun JDY, Middleton JC, Feltner C, Taylor-Phillips S, Barclay C, Dotson A, Baker C, Balio CP, Voisin CE, Harris RP. Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021;326:744-60. [PMID: 34427595 DOI: 10.1001/jama.2021.10403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
38 Escalada San Martín J. Prediabetes: what are we talking about? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:305-308. [DOI: 10.1515/almed-2021-0034] [Reference Citation Analysis]
39 Escalada San Martín J. Prediabetes ¿de qué estamos hablando? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:309-312. [DOI: 10.1515/almed-2021-0030] [Reference Citation Analysis]
40 Ha J, Choi DW, Kim KY, Nam CM, Kim E. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. Cardiovasc Diabetol 2021;20:152. [PMID: 34315501 DOI: 10.1186/s12933-021-01339-x] [Reference Citation Analysis]
41 Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig 2020;11:1020-76. [PMID: 33021749 DOI: 10.1111/jdi.13306] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 80.0] [Reference Citation Analysis]
42 Rapoport M, Chetrit A, Cantrell D, Novikov I, Roth J, Dankner R. Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension. BMJ Open Diabetes Res Care 2021;9:e001981. [PMID: 33692115 DOI: 10.1136/bmjdrc-2020-001981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kim WJ. Recent Perspective on Thiazolidinedione. J Korean Diabetes 2021;22:97-104. [DOI: 10.4093/jkd.2021.22.2.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Nusca A, Tuccinardi D, Pieralice S, Giannone S, Carpenito M, Monte L, Watanabe M, Cavallari I, Maddaloni E, Ussia GP, Manfrini S, Grigioni F. Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Front Pharmacol 2021;12:670155. [PMID: 34054542 DOI: 10.3389/fphar.2021.670155] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
45 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 96] [Cited by in F6Publishing: 109] [Article Influence: 96.0] [Reference Citation Analysis]
46 Alvarez-Canales MFL, Salazar-López SS, Farfán-Vázquez D, Martínez-López YE, González-Mena JN, Jiménez-Ceja LM, Vargas-Ortiz K, Evia-Viscarra ML, Montes de Oca-Loyola ML, Folli F, Aguilar-García A, Guardado-Mendoza R. Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle. Sci Rep 2021;11:8750. [PMID: 33888772 DOI: 10.1038/s41598-021-88108-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel) 2021;11:689. [PMID: 33921359 DOI: 10.3390/diagnostics11040689] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
48 Qin N, Zhou Z, Zhao W, Zou K, Shi W, Yu C, Liu X, Dong Z, Mao Y, Liu X, Sheng J, Ding G, Wu Y, Huang H. Abnormal Glucose Metabolism in Male Mice Offspring Conceived by in vitro Fertilization and Frozen-Thawed Embryo Transfer. Front Cell Dev Biol 2021;9:637781. [PMID: 33634140 DOI: 10.3389/fcell.2021.637781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
49 Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open 2021;4:e2033457. [PMID: 33439265 DOI: 10.1001/jamanetworkopen.2020.33457] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 38.0] [Reference Citation Analysis]
50 Won JC. Thiazolidinediones (TZDs). Stroke Revisited 2021. [DOI: 10.1007/978-981-16-5123-6_11] [Reference Citation Analysis]
51 Moon JH, Lim S. Pharmacotherapy for patients with diabetes mellitus. J Korean Med Assoc 2020;63:766-75. [DOI: 10.5124/jkma.2020.63.12.766] [Reference Citation Analysis]
52 Kim DY, Moon SH, Han JH, Kim MJ, Oh SJ, Bharti D, Lee SH, Park JK, Rho GJ, Jeon BG. Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells. Anim Cells Syst (Seoul) 2020;24:329-40. [PMID: 33456717 DOI: 10.1080/19768354.2020.1847731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2020;11:CD013516. [PMID: 33210751 DOI: 10.1002/14651858.CD013516.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Bowker N, Shah RL, Sharp SJ, Luan J, Stewart ID, Wheeler E, Ferreira MAR, Baras A, Wareham NJ, Langenberg C, Lotta LA. Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes. EBioMedicine 2020;61:103062. [PMID: 33096487 DOI: 10.1016/j.ebiom.2020.103062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
55 Scheen AJ. Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ? Médecine des Maladies Métaboliques 2020;14:549-557. [DOI: 10.1016/j.mmm.2020.05.005] [Reference Citation Analysis]
56 Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, Ma JY, Xu Y, Gao YN, Sun Y, Fan W, Liu W. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab 2021;106:e1420-32. [PMID: 32995892 DOI: 10.1210/clinem/dgaa692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
57 Mahtani AA, Jacob C, Lakshmanan R. Prevalence of diabetes among patients and the assessment of the awareness of the bidirectional relation between diabetes and periodontal disease. J Family Med Prim Care 2020;9:2774-80. [PMID: 32984124 DOI: 10.4103/jfmpc.jfmpc_63_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Nyenwe E, James D, Wan J, Dagogo-Jack S. Glycemic Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Subjects With Parental Diabetes. J Endocr Soc 2020;4:bvaa137. [PMID: 33134765 DOI: 10.1210/jendso/bvaa137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Hall JA, Ramachandran D, Roh HC, DiSpirito JR, Belchior T, Zushin PH, Palmer C, Hong S, Mina AI, Liu B, Deng Z, Aryal P, Jacobs C, Tenen D, Brown CW, Charles JF, Shulman GI, Kahn BB, Tsai LTY, Rosen ED, Spiegelman BM, Banks AS. Obesity-Linked PPARγ S273 Phosphorylation Promotes Insulin Resistance through Growth Differentiation Factor 3. Cell Metab 2020;32:665-675.e6. [PMID: 32941798 DOI: 10.1016/j.cmet.2020.08.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
60 Ravindrarajah R, Reeves D, Howarth E, Meacock R, Soiland-Reyes C, Cotterill S, Whittaker W, Heller S, Sutton M, Bower P, Kontopantelis E. Epidemiology and determinants of non-diabetic hyperglycaemia and its conversion to type 2 diabetes mellitus, 2000-2015: cohort population study using UK electronic health records. BMJ Open 2020;10:e040201. [PMID: 32893192 DOI: 10.1136/bmjopen-2020-040201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-705. [PMID: 32321858 DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 168] [Cited by in F6Publishing: 175] [Article Influence: 84.0] [Reference Citation Analysis]
62 Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int 2020;11:165-223. [PMID: 32802702 DOI: 10.1007/s13340-020-00439-5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 112] [Article Influence: 48.5] [Reference Citation Analysis]
63 Romeo GR, Lee J, Mulla CM, Noh Y, Holden C, Lee BC. Influence of Cinnamon on Glycemic Control in Individuals With Prediabetes: A Randomized Controlled Trial. J Endocr Soc 2020;4:bvaa094. [PMID: 33123653 DOI: 10.1210/jendso/bvaa094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
65 Li YP, Xiao J, Liang X, Pei Y, Han XF, Li CX, Tian H. DPP-4 inhibition resembles exercise in preventing type 2 diabetes development by inhibiting hepatic protein kinase Cε expression in a mouse model of hyperinsulinemia. J Int Med Res 2020;48:300060520934635. [PMID: 32588693 DOI: 10.1177/0300060520934635] [Reference Citation Analysis]
66 Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, Liao X, Lonn E, Gerstein HC, Yusuf S, Brouwers FP, Asselbergs FW, van Gilst W, Anderssen SA, Grobbee DE, Kastelein JJP, Visseren FLJ, Ntaios G, Hatzitolios AI, Savopoulos C, Nieuwkerk PT, Stroes E, Walters M, Higgins P, Dawson J, Gresele P, Guglielmini G, Migliacci R, Ezhov M, Safarova M, Balakhonova T, Sato E, Amaha M, Nakamura T, Kapellas K, Jamieson LM, Skilton M, Blumenthal JA, Hinderliter A, Sherwood A, Smith PJ, van Agtmael MA, Reiss P, van Vonderen MGA, Kiechl S, Klingenschmid G, Sitzer M, Stehouwer CDA, Uthoff H, Zou ZY, Cunha AR, Neves MF, Witham MD, Park HW, Lee MS, Bae JH, Bernal E, Wachtell K, Kjeldsen SE, Olsen MH, Preiss D, Sattar N, Beishuizen E, Huisman MV, Espeland MA, Schmidt C, Agewall S, Ok E, Aşçi G, de Groot E, Grooteman MPC, Blankestijn PJ, Bots ML, Sweeting MJ, Thompson SG, Lorenz MW; PROG-IMT and the Proof-ATHERO Study Groups. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation 2020;142:621-42. [PMID: 32546049 DOI: 10.1161/CIRCULATIONAHA.120.046361] [Cited by in Crossref: 117] [Cited by in F6Publishing: 127] [Article Influence: 58.5] [Reference Citation Analysis]
67 Bostock-cox B. Pre-diabetes and cardiovascular risk: detonating the time bomb. Practice Nursing 2020;31:200-205. [DOI: 10.12968/pnur.2020.31.5.200] [Reference Citation Analysis]
68 Gabriel R, Boukichou Abdelkader N, Acosta T, Gilis-Januszewska A, Gómez-Huelgas R, Makrilakis K, Kamenov Z, Paulweber B, Satman I, Djordjevic P, Alkandari A, Mitrakou A, Lalic N, Colagiuri S, Lindström J, Egido J, Natali A, Pastor JC, Teuschl Y, Lind M, Silva L, López-Ridaura R, Tuomilehto J; e-PREDICE Consortium. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS One 2020;15:e0231196. [PMID: 32282852 DOI: 10.1371/journal.pone.0231196] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
69 Sallar A, Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: State of the science. Exp Biol Med (Maywood) 2020;245:889-96. [PMID: 32212859 DOI: 10.1177/1535370220915644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
70 Schwartz GG, Leiter LA, Ballantyne CM, Barter PJ, Black DM, Kallend D, Laghrissi-Thode F, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Preiss D, Shah PK, Tardif JC, Kittelson J. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care 2020;43:1077-84. [PMID: 32144166 DOI: 10.2337/dc19-2204] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
71 Hall JA, Ramachandran D, Roh HC, Dispirito JR, Belchior T, Zushin PH, Palmer CJ, Hong S, Mina AI, Liu B, Deng Z, Aryal P, Jacobs C, Tenen D, Brown CW, Charles JF, Shulman GI, Kahn BB, Tsai LT, Rosen ED, Spiegelman BM, Banks AS. Obesity-linked PPARγ S273 phosphorylation promotes insulin resistance through Growth Differentiation Factor 3.. [DOI: 10.1101/2020.01.13.904953] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Kim JD, Lee W. Prevention of Type 2 Diabetes. Cardiovasc Prev Pharmacother 2020;2:63. [DOI: 10.36011/cpp.2020.2.e10] [Reference Citation Analysis]
73 Scorletti E, Byrne CD. NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. Non-Alcoholic Fatty Liver Disease 2020. [DOI: 10.1007/978-3-319-95828-6_9] [Reference Citation Analysis]
74 Knowler WC, Crandall JP. Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Curr Diab Rep 2019;19:154. [PMID: 31792721 DOI: 10.1007/s11892-019-1268-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep 2019;19:151. [PMID: 31776781 DOI: 10.1007/s11892-019-1270-y] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 32.3] [Reference Citation Analysis]
76 Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz ES, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN; IRIS Investigators. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018;138:1210-20. [PMID: 29934374 DOI: 10.1161/CIRCULATIONAHA.118.034763] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
77 Harreiter J, Roden M. [Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)]. Wien Klin Wochenschr 2019;131:6-15. [PMID: 30980151 DOI: 10.1007/s00508-019-1450-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 18.0] [Reference Citation Analysis]
78 Inzucchi SE, Viscoli CM, Young LH, Kernan WN. Diabetes prevention and cardiovascular complications. Diabetologia 2019;62:2161-2. [PMID: 31522231 DOI: 10.1007/s00125-019-04999-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circ Res 2018;122:1135-50. [PMID: 29650631 DOI: 10.1161/CIRCRESAHA.118.311912] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
80 Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55. [PMID: 31470636 DOI: 10.3390/medicina55090546] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 25.7] [Reference Citation Analysis]
81 Iskandar S, Migahid A, Kamal D, Megahed O, DeFronzo RA, Zirie M, Jayyousi A, Al Jaidah M, Abdul-Ghani M. Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population. BMC Endocr Disord 2019;19:87. [PMID: 31438915 DOI: 10.1186/s12902-019-0412-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
82 Salukhov VV, Romashevsky BV. Modern aspects for preventive therapy of type 2 diabetes mellitus. Medicinskij sovet 2019. [DOI: 10.21518/2079-701x-2019-4-6-13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Barthow C, Hood F, McKinlay E, Hilder J, Cleghorn C, Huthwaite M, Weatherall M, Parry-Strong A, Pullon S, Gray B, Wickens K, Crane J, Krebs J. Food 4 Health - He Oranga Kai: Assessing the efficacy, acceptability and economic implications of Lactobacillus rhamnosus HN001 and β-glucan to improve glycated haemoglobin, metabolic health, and general well-being in adults with pre-diabetes: study protocol for a 2 × 2 factorial design, parallel group, placebo-controlled randomized controlled trial, with embedded qualitative study and economic analysis. Trials 2019;20:464. [PMID: 31358022 DOI: 10.1186/s13063-019-3553-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
84 Shaw JE. Prediabetes: lifestyle, pharmacotherapy or regulation? Ther Adv Endocrinol Metab 2019;10:2042018819863020. [PMID: 31321022 DOI: 10.1177/2042018819863020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
85 Sheng Z, Cao JY, Pang YC, Xu HC, Chen JW, Yuan JH, Wang R, Zhang CS, Wang LX, Dong J. Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2019;10:455. [PMID: 31354627 DOI: 10.3389/fendo.2019.00455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
86 Nathan DM, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, Knowler WC, Mather KJ, Mudaliar S, Orchard TJ, Temprosa M, White NH; Research Group. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia 2019;62:1319-28. [PMID: 31270584 DOI: 10.1007/s00125-019-4928-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
87 Watkins K, Griffin OH, Gardner EA. Investigation of black box drugs purchased from an online pharmacy. Journal of Substance Use 2019;24:445-449. [DOI: 10.1080/14659891.2019.1595197] [Reference Citation Analysis]
88 Yamaoka K, Nemoto A, Tango T. Comparison of the Effectiveness of Lifestyle Modification with Other Treatments on the Incidence of Type 2 Diabetes in People at High Risk: A Network Meta-Analysis. Nutrients 2019;11:E1373. [PMID: 31248094 DOI: 10.3390/nu11061373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
89 RISE Consortium. Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 2019;42:1742-51. [PMID: 31178434 DOI: 10.2337/dc19-0556] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
90 Zand A, Ibrahim K, Patham B. Prediabetes: Why Should We Care? Methodist Debakey Cardiovasc J 2018;14:289-97. [PMID: 30788015 DOI: 10.14797/mdcj-14-4-289] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
91 Nesti L, Mengozzi A, Tricò D. Impact of Nutrient Type and Sequence on Glucose Tolerance: Physiological Insights and Therapeutic Implications. Front Endocrinol (Lausanne) 2019;10:144. [PMID: 30906282 DOI: 10.3389/fendo.2019.00144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
92 Tricò D, Galderisi A, Mari A, Santoro N, Caprio S. One-hour post-load plasma glucose predicts progression to prediabetes in a multi-ethnic cohort of obese youths. Diabetes Obes Metab 2019;21:1191-8. [PMID: 30663201 DOI: 10.1111/dom.13640] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
93 Miao S, Dong X, Zhang X, Jing S, Zhang X, Xu T, Wang L, Du X, Xu H, Liu Y. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes. J Diabetes 2019;11:684-9. [PMID: 30597747 DOI: 10.1111/1753-0407.12894] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
94 Carris NW, Magness RR, Labovitz AJ. Prevention of Diabetes Mellitus in Patients With Prediabetes. Am J Cardiol 2019;123:507-12. [PMID: 30528418 DOI: 10.1016/j.amjcard.2018.10.032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
95 Brannick B, Dagogo-Jack S. Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. Endocrinol Metab Clin North Am 2018;47:33-50. [PMID: 29407055 DOI: 10.1016/j.ecl.2017.10.001] [Cited by in Crossref: 91] [Cited by in F6Publishing: 105] [Article Influence: 30.3] [Reference Citation Analysis]
96 Lam YWF, Duggirala R, Jenkinson CP, Arya R. The Role of Pharmacogenomics in Diabetes. Pharmacogenomics 2019. [DOI: 10.1016/b978-0-12-812626-4.00009-7] [Reference Citation Analysis]
97 Kohda Y, Matsumura H. Obesity-related hypertension and enhanced plasma orexin-A level are attenuated by the consumption of thiamine water in diabetic rats under cerebral oxidative stress conditions. Fundam Toxicol Sci 2019;6:383-390. [DOI: 10.2131/fts.6.383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Distefano JK, Watanabe RM. Pharmacoepigenetics in Type 2 Diabetes Mellitus. Pharmacoepigenetics 2019. [DOI: 10.1016/b978-0-12-813939-4.00018-8] [Reference Citation Analysis]
99 Wong VW, Mok MT, Cheng AS. Histone Deacetylase HDAC8 and Insulin Resistance. Handbook of Nutrition, Diet, and Epigenetics 2019. [DOI: 10.1007/978-3-319-55530-0_23] [Reference Citation Analysis]
100 Cook CB, Chakkera H. Diabetes Mellitus and Renal Transplantation. Endocrine Disorders in Kidney Disease 2019. [DOI: 10.1007/978-3-319-97765-2_6] [Reference Citation Analysis]
101 Shukla A, Mandel L. A Patient with High Cardiometabolic Risk. Obesity Management 2019. [DOI: 10.1007/978-3-030-01039-3_3] [Reference Citation Analysis]
102 Fagg J, Valabhji J. How do we identify people at high risk of Type 2 diabetes and help prevent the condition from developing? Diabet Med 2019;36:316-25. [PMID: 30466172 DOI: 10.1111/dme.13867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
103 American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S29-33. [PMID: 30559229 DOI: 10.2337/dc19-S003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 22.8] [Reference Citation Analysis]
104 Rhee SY, Chon S, Ahn KJ, Woo JT; Korean Diabetes Prevention Study Investigators. Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. Diabetes Metab J 2019;43:49-58. [PMID: 30398039 DOI: 10.4093/dmj.2018.0033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
105 Pedro-Botet J, Ascaso JF, Barrios V, De la Sierra A, Escalada J, Millán J, Mostaza JM, Pérez-Martínez P, Pintó X, Salas-Salvadó J, Valdivielso P. COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes Metab Syndr Obes 2018;11:683-97. [PMID: 30464566 DOI: 10.2147/DMSO.S165740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
106 Xiang AH, Trigo E, Martinez M, Katkhouda N, Beale E, Wang X, Wu J, Chow T, Montgomery C, Nayak KS, Hendee F, Buchanan TA; RISE Consortium., RISE Collaborators. Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care 2018;41:2544-51. [PMID: 30282699 DOI: 10.2337/dc18-1662] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
107 Ryder REJ. Real-world diabetes prevention: from theory to practice. The Lancet Diabetes & Endocrinology 2018;6:756-7. [DOI: 10.1016/s2213-8587(18)30267-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
108 Hua H, Yang J, Lin H, Xi Y, Dai M, Xu G, Wang F, Liu L, Zhao T, Huang J, Gonzalez FJ, Liu A. PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. J Pharm Pharmacol 2018;70:1630-42. [PMID: 30251457 DOI: 10.1111/jphp.13014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
109 Echouffo-Tcheugui JB, Kengne AP, Ali MK. Issues in Defining the Burden of Prediabetes Globally. Curr Diab Rep 2018;18:105. [PMID: 30229351 DOI: 10.1007/s11892-018-1089-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
110 Dugan J, Cantillep A, Newberry K, Shubrook J. A call to action on prediabetes. JAAPA 2018;31:26-30. [PMID: 30204618 DOI: 10.1097/01.JAA.0000545064.33107.8f] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Tong YZ, Tong NW, Teng WP, Mu YM, Zhao JJ, Shan ZY, Ning G; Chinese Society of Endocrinology. Consensus on the Prevention of Type 2 Diabetes in Chinese Adults. Chin Med J (Engl) 2017;130:600-6. [PMID: 28229993 DOI: 10.4103/0366-6999.200532] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
112 Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. Int J Mol Sci. 2018;19. [PMID: 30011790 DOI: 10.3390/ijms19072034] [Cited by in Crossref: 78] [Cited by in F6Publishing: 85] [Article Influence: 19.5] [Reference Citation Analysis]
113 Fajtova V. Short-Term Sitagliptin-Metformin Therapy is More Effective Than Metformin or Placebo in Prior Gestational Diabetic Women With Impaired Glucose Regulation. Endocrine Practice 2018;24:695-697. [DOI: 10.4158/ep-2018-0103] [Reference Citation Analysis]
114 Mehtälä J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int 2019;10:24-36. [PMID: 30800561 DOI: 10.1007/s13340-018-0360-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
115 Salunkhe VA, Veluthakal R, Kahn SE, Thurmond DC. Novel approaches to restore beta cell function in prediabetes and type 2 diabetes. Diabetologia 2018;61:1895-901. [PMID: 29947922 DOI: 10.1007/s00125-018-4658-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
116 Abdul-Ghani M, Jayyous A, Asaad N, Helmy S, Al-Suwaidi J. Pioglitazone and cardiovascular risk in T2DM patients: is it good for all? Ann Transl Med 2018;6:192. [PMID: 29951514 DOI: 10.21037/atm.2018.03.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 Clarke GD, Molina-Wilkins M, Solis-Herrera C, Mendez V, Monroy A, Cersosimo E, Chilton RJ, Abdul-Ghani M, DeFronzo RA. Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. Endocrinol Diabetes Metab 2018;1:e00014. [PMID: 30815550 DOI: 10.1002/edm2.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
118 Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Japanese Clinical Practice Guideline for Diabetes 2016. Diabetol Int 2018;9:1-45. [PMID: 30603347 DOI: 10.1007/s13340-018-0345-3] [Cited by in Crossref: 126] [Cited by in F6Publishing: 105] [Article Influence: 31.5] [Reference Citation Analysis]
119 Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Japanese Clinical Practice Guideline for Diabetes 2016. J Diabetes Investig 2018. [PMID: 29582574 DOI: 10.1111/jdi.12810] [Cited by in Crossref: 137] [Cited by in F6Publishing: 144] [Article Influence: 34.3] [Reference Citation Analysis]
120 Tanaka A, Komukai S, Shibata Y, Yokoi H, Iwasaki Y, Kawasaki T, Horiuchi K, Nakao K, Ueno T, Nakashima H, Tamashiro M, Hikichi Y, Shimomura M, Tago M, Toyoda S, Inoue T, Kawaguchi A, Node K; Pioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators. Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial. Heart Vessels 2018;33:965-77. [PMID: 29487991 DOI: 10.1007/s00380-018-1143-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
121 Hirukawa H, Hashiramoto M, Tanizawa Y, Kaku K; Pioglitazone and Sulfonylurea Remission from Type 2 Diabetes Mellitus and Anti-Atherosclerosis in Japan (PREVENT-J) study group. Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes. J Diabetes Investig 2018;9:1119-27. [PMID: 29406607 DOI: 10.1111/jdi.12813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
122 Chatterjee S, Davies M, Khunti K. Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. Am J Cardiovasc Drugs 2018;18:13-24. [PMID: 28762143 DOI: 10.1007/s40256-017-0239-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
123 Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, Zhu D, Chen L, Chen L, Guo L, Guo X, Ji Q, Li Q, Li X, Liu J, Ran X, Shan Z, Shi L, Song G, Yang L, Yang Y, Yang W; Chinese Diabetes Society. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev 2016;32:442-58. [PMID: 27464265 DOI: 10.1002/dmrr.2827] [Cited by in Crossref: 187] [Cited by in F6Publishing: 204] [Article Influence: 46.8] [Reference Citation Analysis]
124 Bianchi C, Daniele G, Dardano A, Del Prato S. Treatment with Oral Drugs. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_19] [Reference Citation Analysis]
125 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_16-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Watanabe RM. Physiologic Interpretation of GWAS Signals for Type 2 Diabetes. Methods in Molecular Biology 2018. [DOI: 10.1007/978-1-4939-7471-9_18] [Reference Citation Analysis]
127 Bianchi C, Daniele G, Dardano A, Del Prato S. Treatment with Oral Drugs. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_19-1] [Reference Citation Analysis]
128 Perreault L. Prevention of Type 2 Diabetes. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_2] [Reference Citation Analysis]
129 Joung H, Kwon H. Pharmacological Intervention for the Prevention of Diabetes Mellitus. J Korean Diabetes 2018;19:140. [DOI: 10.4093/jkd.2018.19.3.140] [Reference Citation Analysis]
130 Defronzo RA. Pathogenesis of Type 2 Diabetes Mellitus. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_8-1] [Reference Citation Analysis]
131 Defronzo RA. Pathogenesis of Type 2 Diabetes Mellitus. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_8] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
132 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_16] [Reference Citation Analysis]
133 Wu Y, Li P, Zhang D, Sun Y. Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. Exp Ther Med 2018;15:2120-7. [PMID: 29434814 DOI: 10.3892/etm.2017.5650] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
134 Peloso A, Citro A, Oldani G, Brambilla S, Piemonti L, Cobianchi L. Bioengineering the Pancreas: Cell-on-Scaffold Technology. Scaffolds in Tissue Engineering - Materials, Technologies and Clinical Applications 2017. [DOI: 10.5772/intechopen.70990] [Reference Citation Analysis]
135 Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KMV, Ali MK. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017;177:1808-17. [PMID: 29114778 DOI: 10.1001/jamainternmed.2017.6040] [Cited by in Crossref: 167] [Cited by in F6Publishing: 173] [Article Influence: 33.4] [Reference Citation Analysis]
136 Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813-20. [PMID: 28637886 DOI: 10.2337/dc16-2736] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 15.8] [Reference Citation Analysis]
137 Inaishi J, Saisho Y. Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes. J Clin Med 2017;6:E113. [PMID: 29483484 DOI: 10.3390/jcm6120113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
138 Filipova E, Uzunova K, Kalinov K, Vekov T. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr. 2017;9:90. [PMID: 29163673 DOI: 10.1186/s13098-017-0290-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
139 Avilés-Santa ML, Colón-Ramos U, Lindberg NM, Mattei J, Pasquel FJ, Pérez CM. From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America. Front Endocrinol (Lausanne) 2017;8:298. [PMID: 29176960 DOI: 10.3389/fendo.2017.00298] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
140 Naito Y, Yoshikawa Y, Yoshizawa K, Takenouchi A, Yasui H. Beneficial Effect of Bis(Hinokitiolato)Zn Complex on High-fat Diet-induced Lipid Accumulation in Mouse Liver and Kidney. In Vivo 2017;31:1145-51. [PMID: 29102937 DOI: 10.21873/invivo.11181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
141 de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol 2017;16:134. [PMID: 29037211 DOI: 10.1186/s12933-017-0617-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 13.4] [Reference Citation Analysis]
142 Nauck MA, Meier JJ. Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. Lancet Diabetes Endocrinol 2017;5:843-5. [PMID: 28917542 DOI: 10.1016/S2213-8587(17)30318-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
143 Herman WH. The global agenda for the prevention of type 2 diabetes. Nutr Rev 2017;75:13-8. [PMID: 28049746 DOI: 10.1093/nutrit/nuw034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
144 Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017;60:1601-11. [PMID: 28770322 DOI: 10.1007/s00125-017-4361-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 17.6] [Reference Citation Analysis]
145 Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, Berdunov V, Guha IN, Elliott RA. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7:e015659. [PMID: 28679676 DOI: 10.1136/bmjopen-2016-015659] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
146 Ko KD, Kim KK, Lee KR. Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health? J Obes Metab Syndr 2017;26:102-6. [PMID: 31089503 DOI: 10.7570/jomes.2017.26.2.102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
147 Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 2016;241:1323-31. [PMID: 27302176 DOI: 10.1177/1535370216654227] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
148 Ismail-Beigi F, Moghissi E, Kosiborod M, Inzucchi SE. Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. J Gen Intern Med 2017;32:1044-51. [PMID: 28550608 DOI: 10.1007/s11606-017-4061-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
149 Perdigoto AL, Young LH, Inzucchi SE. Pioglitazone and cardiovascular risk reduction: time for a second look? Cardiovasc Endocrinol 2017;6:55-61. [PMID: 31646121 DOI: 10.1097/XCE.0000000000000110] [Reference Citation Analysis]
150 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;5:CD012204. [PMID: 28489279 DOI: 10.1002/14651858.CD012204.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
151 le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399-409. [PMID: 28237263 DOI: 10.1016/S0140-6736(17)30069-7] [Cited by in Crossref: 359] [Cited by in F6Publishing: 364] [Article Influence: 71.8] [Reference Citation Analysis]
152 Krentz AJ, Scuteri A. Insulin resistance and the metabolic syndrome. Diabetes in Old Age 2017. [DOI: 10.1002/9781118954621.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Horton ES. Preventative strategies. Diabetes in Old Age 2017. [DOI: 10.1002/9781118954621.ch3] [Reference Citation Analysis]
154 Yokota T, Kinugawa S, Hirabayashi K, Suga T, Takada S, Omokawa M, Kadoguchi T, Takahashi M, Fukushima A, Matsushima S. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J Diabetes Investig. 2017;8:535-541. [PMID: 27930876 DOI: 10.1111/jdi.12606] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
155 Chandra M, Miriyala S, Panchatcharam M. PPARγ and Its Role in Cardiovascular Diseases. PPAR Res 2017;2017:6404638. [PMID: 28243251 DOI: 10.1155/2017/6404638] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
156 Shannon CE, Daniele G, Galindo C, Abdul-Ghani MA, DeFronzo RA, Norton L. Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. FEBS J 2017;284:451-65. [PMID: 27987376 DOI: 10.1111/febs.13992] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
157 Abdul-Ghani M, Migahid O, Megahed A, Adams J, Triplitt C, DeFronzo RA, Zirie M, Jayyousi A. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-31. [PMID: 28096223 DOI: 10.2337/dc16-1738] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
158 Luo Y, Paul SK, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Wang H. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. J Diabetes Res 2017;2017:7602408. [PMID: 28168204 DOI: 10.1155/2017/7602408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
159 Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7:e013927. [PMID: 28057658 DOI: 10.1136/bmjopen-2016-013927] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 21.0] [Reference Citation Analysis]
160 Farr OM, Mantzoros CS. Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism 2017;70:192-5. [PMID: 28095990 DOI: 10.1016/j.metabol.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
161 Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest 2017;127:83-93. [PMID: 28045401 DOI: 10.1172/JCI88884] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 19.8] [Reference Citation Analysis]
162 Dagogo-jack S. Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. Diabetes Mellitus in Developing Countries and Underserved Communities 2017. [DOI: 10.1007/978-3-319-41559-8_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
163 Wong VW, Mok MT, Cheng AS. Histone Deacetylase HDAC8 and Insulin Resistance. Handbook of Nutrition, Diet, and Epigenetics 2017. [DOI: 10.1007/978-3-319-31143-2_23-1] [Reference Citation Analysis]
164 Bray GA. Obesity and the Risk for Type 2 Diabetes. Nutrition in the Prevention and Treatment of Disease 2017. [DOI: 10.1016/b978-0-12-802928-2.00030-8] [Reference Citation Analysis]
165 Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, Gaulton KJ, Eicher JD, Sharp SJ, Luan J, De Lucia Rolfe E, Stewart ID, Wheeler E, Willems SM, Adams C, Yaghootkar H, Forouhi NG, Khaw KT, Johnson AD, Semple RK, Frayling T, Perry JR, Dermitzakis E, McCarthy MI, Barroso I, Wareham NJ, Savage DB, Langenberg C, O'Rahilly S, Scott RA; EPIC-InterAct Consortium., Cambridge FPLD1 Consortium. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 2017;49:17-26. [PMID: 27841877 DOI: 10.1038/ng.3714] [Cited by in Crossref: 338] [Cited by in F6Publishing: 346] [Article Influence: 56.3] [Reference Citation Analysis]
166 Guimarães J. Diabetes-Old Therapies Revisited. EMIJ 2016;3. [DOI: 10.15406/emij.2016.03.00056] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
167 Stentz FB, Brewer A, Wan J, Garber C, Daniels B, Sands C, Kitabchi AE. Remission of pre-diabetes to normal glucose tolerance in obese adults with high protein versus high carbohydrate diet: randomized control trial. BMJ Open Diabetes Res Care 2016;4:e000258. [PMID: 27843552 DOI: 10.1136/bmjdrc-2016-000258] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
168 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2016;10:CD012151. [PMID: 27749986 DOI: 10.1002/14651858.CD012151.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
169 Hu X, Reaven PD, Saremi A, Liu N, Abbasi MA, Liu H, Migrino RQ; ACT NOW Study Investigators. Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance. EURASIP J Bioinform Syst Biol 2016;2016:14. [PMID: 27642290 DOI: 10.1186/s13637-016-0049-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
170 Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr) 2016;38:485-93. [PMID: 27585671 DOI: 10.1007/s11357-016-9946-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
171 Stump M, Guo DF, Lu KT, Mukohda M, Cassell MD, Norris AW, Rahmouni K, Sigmund CD. Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development. Endocrinology 2016;157:4266-75. [PMID: 27575030 DOI: 10.1210/en.2016-1524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
172 Kramer CK, Zinman B, Choi H, Retnakaran R. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care 2016;4:e000270. [PMID: 27547422 DOI: 10.1136/bmjdrc-2016-000270] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
173 Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-92. [PMID: 27465265 DOI: 10.2337/dc16-0798] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
174 Scherbaum WA. α-Glukosidase-Hemmer und Thiazolidindione (Glitazone). Diabetologe 2016;12:178-183. [DOI: 10.1007/s11428-016-0085-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
175 Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59:1112-1120. [PMID: 27101131 DOI: 10.1007/s00125-016-3952-1] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 15.2] [Reference Citation Analysis]
176 Portillo-Sanchez P, Cusi K. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clin Diabetes Endocrinol 2016;2:9. [PMID: 28702244 DOI: 10.1186/s40842-016-0027-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
177 Manaf A, Tjandrawinata RR, Malinda D. Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa. Drug Des Devel Ther 2016;10:1279-89. [PMID: 27099473 DOI: 10.2147/DDDT.S97568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
178 Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. J Clin Endocrinol Metab. 2016;101:2056-2062. [PMID: 26982008 DOI: 10.1210/jc.2015-4202] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
179 Koska J, Yassine H, Trenchevska O, Sinari S, Schwenke DC, Yen FT, Billheimer D, Nelson RW, Nedelkov D, Reaven PD. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J Lipid Res 2016;57:894-905. [PMID: 26945091 DOI: 10.1194/jlr.P064816] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
180 Pollak C. F. RESISTENCIA A LA INSULINA: VERDADES Y CONTROVERSIAS. Revista Médica Clínica Las Condes 2016;27:171-8. [DOI: 10.1016/j.rmclc.2016.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
181 Musi N, Bartke A. Diabetes and Aging. Advances in Geroscience 2016. [DOI: 10.1007/978-3-319-23246-1_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
182 Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J 2015;62:77-86. [PMID: 25328035 DOI: 10.1507/endocrj.EJ14-0335] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
183 Stempa O. Pioglitazone: lessons and learnings 15 years since launch and beyond. Diabetes Management 2015;5:415-429. [DOI: 10.2217/dmt.15.38] [Reference Citation Analysis]
184 Huang J, Ou HY, Lin J, Karnchanasorn R, Feng W, Samoa R, Chuang LM, Chiu KC. The Impact of Hepatitis B Vaccination Status on the Risk of Diabetes, Implicating Diabetes Risk Reduction by Successful Vaccination. PLoS One 2015;10:e0139730. [PMID: 26509504 DOI: 10.1371/journal.pone.0139730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
185 Lee WS, Kim J. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Res 2015;2015:271983. [PMID: 26587015 DOI: 10.1155/2015/271983] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
186 Schwarz PE. [Screening and prevention of diabetes]. Internist (Berl) 2015;56:1124-33. [PMID: 26428521 DOI: 10.1007/s00108-015-3737-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Courtney MR, Moler EJ, Osborne JA, Whitney G, Conard SE. An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting. Diabetes Metab Syndr Obes 2015;8:447-53. [PMID: 26425102 DOI: 10.2147/DMSO.S78810] [Reference Citation Analysis]
188 Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 [PMID: 26464759 DOI: 10.4239/wjd.v6.i12.1207] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
189 Liu Y, Cotillard A, Vatier C, Bastard JP, Fellahi S, Stévant M, Allatif O, Langlois C, Bieuvelet S, Brochot A, Guilbot A, Clément K, Rizkalla SW. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One 2015;10:e0138646. [PMID: 26406981 DOI: 10.1371/journal.pone.0138646] [Cited by in Crossref: 31] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
190 Filipova EP, Uzunova KH, Vekov TY. Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. Diabetol Metab Syndr 2015;7:63. [PMID: 26288659 DOI: 10.1186/s13098-015-0059-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE. Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Curr Ther Res Clin Exp 2015;77:83-9. [PMID: 26543510 DOI: 10.1016/j.curtheres.2015.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
192 Holt RI. The prevention of diabetes and cardiovascular disease in people with schizophrenia. Acta Psychiatr Scand 2015;132:86-96. [PMID: 25976975 DOI: 10.1111/acps.12443] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
193 Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia 2015;58:2336-43. [PMID: 26197707 DOI: 10.1007/s00125-015-3689-2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
194 Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab 2015;17:1033-41. [PMID: 26094974 DOI: 10.1111/dom.12507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
195 Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis. 2015;242:56-64. [PMID: 26184694 DOI: 10.1016/j.atherosclerosis.2015.06.055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
196 Aroda VR, Getaneh A. Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab 2015;10:381-98. [PMID: 30293496 DOI: 10.1586/17446651.2015.1054280] [Reference Citation Analysis]
197 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. SEMERGEN - Medicina de Familia 2015;41:266-78. [DOI: 10.1016/j.semerg.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
198 Costantino G, Montano N, Casazza G. When should we change our clinical practice based on the results of a clinical study? Study endpoints. Intern Emerg Med 2015;10:875-7. [PMID: 26103938 DOI: 10.1007/s11739-015-1271-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
199 Srinivasan S, Florez JC. Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther 2015;98:162-9. [PMID: 25974616 DOI: 10.1002/cpt.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
200 Cao L, Sun H, Wu H, Lü Q, Mckee AM; Cochrane Metabolic and Endocrine Disorders Group. Pioglitazone for adults with high risk of developing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011759] [Reference Citation Analysis]
201 Trivin C, Metzger M, Haymann JP, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Stengel B, Thervet E; NephroTest Study Group. Glycated Hemoglobin Level and Mortality in a Nondiabetic Population with CKD. Clin J Am Soc Nephrol 2015;10:957-64. [PMID: 25979978 DOI: 10.2215/CJN.08540814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
202 Horita S, Nakamura M, Satoh N, Suzuki M, Seki G. Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention. PPAR Res 2015;2015:646423. [PMID: 26074951 DOI: 10.1155/2015/646423] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
203 Balakrishnan R, Berger JS, Tully L, Vani A, Shah B, Burdowski J, Fisher E, Schwartzbard A, Sedlis S, Weintraub H, Underberg JA, Danoff A, Slater JA, Gianos E. Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. Diabetes Metab Res Rev 2015;31:603-9. [PMID: 25728823 DOI: 10.1002/dmrr.2646] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
204 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía JC, Fornos JA, Girbés J, Rica I. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. Avances en Diabetología 2015;31:89-101. [DOI: 10.1016/j.avdiab.2014.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
205 Anderson RA, Zhan Z, Luo R, Guo X, Guo Q, Zhou J, Kong J, Davis PA, Stoecker BJ. Cinnamon extract lowers glucose, insulin and cholesterol in people with elevated serum glucose. J Tradit Complement Med 2016;6:332-6. [PMID: 27774415 DOI: 10.1016/j.jtcme.2015.03.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
206 Fiorentino TV, Hribal ML, Perticone M, Andreozzi F, Sciacqua A, Perticone F, Sesti G. Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria. Acta Diabetol 2015;52:349-56. [PMID: 25246028 DOI: 10.1007/s00592-014-0647-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
207 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 242] [Cited by in F6Publishing: 256] [Article Influence: 34.6] [Reference Citation Analysis]
208 Abdul-ghani M, Defronzo RA, Eldor R. Combination therapy in type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch46] [Reference Citation Analysis]
209 Mudaliar S, Henry RR. PPAR agonists in the treatment of diabetes. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch44] [Reference Citation Analysis]
210 Yates T, Davies MJ. Prevention of type 2 diabetes. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch38] [Reference Citation Analysis]
211 Defronzo RA. Pathogenesis of type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
212 Mata-Cases M, Artola S, Escalada J, Ezkurra-Loyola P, Ferrer-García JC, Fornos JA, Girbés J, Rica I; Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. [Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. Aten Primaria 2015;47:456-68. [PMID: 25735589 DOI: 10.1016/j.aprim.2014.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
213 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society. Revista Clínica Española (English Edition) 2015;215:117-29. [DOI: 10.1016/j.rceng.2014.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
214 Saisho Y. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes 2015; 6(1): 109-124 [PMID: 25685282 DOI: 10.4239/wjd.v6.i1.109] [Cited by in CrossRef: 119] [Cited by in F6Publishing: 125] [Article Influence: 17.0] [Reference Citation Analysis]
215 Herman WH, Taylor GW, Jacobson JJ, Burke R, Brown MB. Screening for prediabetes and type 2 diabetes in dental offices. J Public Health Dent 2015;75:175-82. [PMID: 25662777 DOI: 10.1111/jphd.12082] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
216 Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab 2015;100:1855-62. [PMID: 25603459 DOI: 10.1210/jc.2014-3824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
217 Nakazawa H, Yamada M, Tanaka T, Kramer J, Yu YM, Fischman AJ, Martyn JA, Tompkins RG, Kaneki M. Role of protein farnesylation in burn-induced metabolic derangements and insulin resistance in mouse skeletal muscle. PLoS One 2015;10:e0116633. [PMID: 25594415 DOI: 10.1371/journal.pone.0116633] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
218 Færch K, Vistisen D, Johansen NB, Jørgensen ME. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep 2014;14:493. [PMID: 24743942 DOI: 10.1007/s11892-014-0493-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
219 Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-75. [PMID: 25425451 DOI: 10.1111/dom.12417] [Cited by in Crossref: 123] [Cited by in F6Publishing: 130] [Article Influence: 17.6] [Reference Citation Analysis]
220 Ajala O, English P. Dietary Management of Pre-Diabetes and Type 2 Diabetes. Glucose Intake and Utilization in Pre-Diabetes and Diabetes 2015. [DOI: 10.1016/b978-0-12-800093-9.00007-7] [Reference Citation Analysis]
221 Tsimihodimos V, Florentin M. Hypertension and Dyslipidemia in Patients with Pre-Diabetes. Glucose Intake and Utilization in Pre-Diabetes and Diabetes 2015. [DOI: 10.1016/b978-0-12-800093-9.00013-2] [Reference Citation Analysis]
222 Chiong Y, Evans-molina C. Vascular Complications of Diabetes Mellitus. PanVascular Medicine 2015. [DOI: 10.1007/978-3-642-37078-6_49] [Reference Citation Analysis]
223 Kernan WN, Viscoli CM, Varughese MC. Litigation seeking access to data from ongoing clinical trials: a threat to clinical research. JAMA Intern Med 2014;174:1502-4. [PMID: 25047222 DOI: 10.1001/jamainternmed.2014.3248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Thakran S, Zhang Q, Morales-Tirado V, Steinle JJ. Pioglitazone restores IGFBP-3 levels through DNA PK in retinal endothelial cells cultured in hyperglycemic conditions. Invest Ophthalmol Vis Sci 2014;56:177-84. [PMID: 25525174 DOI: 10.1167/iovs.14-15550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
225 Sesti G, Fiorentino TV, Succurro E, Perticone M, Arturi F, Sciacqua A, Perticone F. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with unfavorable inflammatory profile. Acta Diabetol 2014;51:927-32. [PMID: 24619654 DOI: 10.1007/s00592-013-0539-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
226 Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN; IRIS Trial investigators. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 2014;168:823-9.e6. [PMID: 25458644 DOI: 10.1016/j.ahj.2014.07.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
227 Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig 2015;6:309-16. [PMID: 25969716 DOI: 10.1111/jdi.12290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
228 Ormseth MJ, Oeser AM, Cunningham A, Bian A, Shintani A, Solus J, Tanner SB, Stein CM. Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy. Arthritis Rheumatol 2014;66:2331-8. [PMID: 24782291 DOI: 10.1002/art.38686] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
229 Sawhney A, Rothkopf M. Metabolic Syndrome. Metabolic Medicine and Surgery 2014. [DOI: 10.1201/b17616-7] [Reference Citation Analysis]
230 Merlotti C, Morabito A, Ceriani V, Pontiroli AE. Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis. Acta Diabetol 2014;51:853-63. [PMID: 25085464 DOI: 10.1007/s00592-014-0624-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
231 Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-8. [PMID: 25249651 DOI: 10.2337/dc14-0893] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 11.4] [Reference Citation Analysis]
232 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-91. [PMID: 25242225 DOI: 10.1016/j.cmet.2014.08.005] [Cited by in Crossref: 312] [Cited by in F6Publishing: 322] [Article Influence: 39.0] [Reference Citation Analysis]
233 Shamsi BH, Ma C, Naqvi S, Xiao Y. Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice. PLoS One 2014;9:e106992. [PMID: 25210844 DOI: 10.1371/journal.pone.0106992] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
234 Goldfine AB, Phua EJ, Abrahamson MJ. Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation. 2014;129:2567-2573. [PMID: 24934464 DOI: 10.1161/circulationaha.113.006634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
235 Stulnig T. Insulintherapie bei Typ-2-Diabetes mellitus. Diabetologe 2014;10:460-465. [DOI: 10.1007/s11428-013-1151-y] [Reference Citation Analysis]
236 Rahimi Naini S, Fuchs M. Non-alcoholic fatty liver disease in patients with diabetes mellitus. Expert Rev Endocrinol Metab 2014;9:503-14. [PMID: 30736212 DOI: 10.1586/17446651.2014.938053] [Reference Citation Analysis]
237 Saisho Y. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med 2014;3:923-43. [PMID: 26237486 DOI: 10.3390/jcm3030923] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
238 . The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). Journal of Endocrinology, Metabolism and Diabetes of South Africa 2014;17:S1-S95. [DOI: 10.1080/22201009.2012.10872287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
239 Sesti G, Hribal ML, Fiorentino TV, Sciacqua A, Perticone F. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care 2014;2:e000016. [PMID: 25452862 DOI: 10.1136/bmjdrc-2014-000016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
240 Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. BMJ 2014;349:g4485. [PMID: 25028385 DOI: 10.1136/bmj.g4485] [Cited by in Crossref: 131] [Cited by in F6Publishing: 144] [Article Influence: 16.4] [Reference Citation Analysis]
241 Cao L, Li J, Wu H, Liu GJ, Dong BR, Lü Q. Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd009989.pub2] [Reference Citation Analysis]
242 Ming Y, Hu X, Song Y, Liu Z, Li J, Gao R, Zhang Y, Mei H, Guo T, Xiao L, Wang B, Wu C, Xiao X. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo. PLoS One 2014;9:e102102. [PMID: 25004107 DOI: 10.1371/journal.pone.0102102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
243 Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, Bergenstal RM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC; ACCORD Group of Investigators. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia 2014;57:2030-7. [PMID: 24985147 DOI: 10.1007/s00125-014-3318-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
244 Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014;37:2622-2631. [PMID: 24969574 DOI: 10.2337/dc14-0656] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
245 Richard AJ, Fuller S, Fedorcenco V, Beyl R, Burris TP, Mynatt R, Ribnicky DM, Stephens JM. Artemisia scoparia enhances adipocyte development and endocrine function in vitro and enhances insulin action in vivo. PLoS One 2014;9:e98897. [PMID: 24915004 DOI: 10.1371/journal.pone.0098897] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
246 Das SK, Sharma NK. Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility. World J Diabetes 2014; 5(2): 97-114 [PMID: 24748924 DOI: 10.4239/wjd.v5.i2.97] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
247 Evans-Molina C, Hatanaka M, Mirmira RG. Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus. Diabetes Obes Metab 2013;15 Suppl 3:159-69. [PMID: 24003933 DOI: 10.1111/dom.12163] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
248 Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013;36 Suppl 2:S155-61. [PMID: 23882041 DOI: 10.2337/dcS13-2031] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 8.0] [Reference Citation Analysis]
249 DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S127-S138. [PMID: 23882037 DOI: 10.2337/dcs13-2011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 187] [Article Influence: 21.4] [Reference Citation Analysis]
250 Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36 Suppl 2:S162-74. [PMID: 23882042 DOI: 10.2337/dcS13-2003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 9.1] [Reference Citation Analysis]
251 Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med 2014;31:1064-8. [PMID: 24646311 DOI: 10.1111/dme.12437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
252 Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. Diabetes Care 2014;37:1706-11. [PMID: 24705615 DOI: 10.2337/dc13-1745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
253 Curtis JM, Knowler WC. Classification, epidemiology, diagnosis, and risk factors of diabetes. Diabetes Mellitus and Oral Health 2014. [DOI: 10.1002/9781118887837.ch2] [Reference Citation Analysis]
254 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
255 Cummings BP, Bettaieb A, Graham JL, Stanhope K, Haj FG, Havel PJ. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. J Endocrinol. 2014;221:133-144. [PMID: 24627447 DOI: 10.1530/joe-13-0601] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
256 Dyson PA. Addressing noncommunicable disease at the population level: a focus on diabetes. Diabetes Management 2014;4:153-163. [DOI: 10.2217/dmt.13.75] [Reference Citation Analysis]
257 Knowler WC, Ackermann RT. Preventing diabetes in American Indian communities. Diabetes Care 2013;36:1820-2. [PMID: 23801794 DOI: 10.2337/dc12-2635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
258 Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329-341. [PMID: 23625197 DOI: 10.1007/s11892-013-0378-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
259 Burotto M, Szabo E. PPARγ in head and neck cancer prevention. Oral Oncol 2014;50:924-9. [PMID: 24434068 DOI: 10.1016/j.oraloncology.2013.12.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
260 Chiong Y, Evans-molina C. Vascular Complications of Diabetes Mellitus. PanVascular Medicine 2014. [DOI: 10.1007/978-3-642-37393-0_49-1] [Reference Citation Analysis]
261 Huang PL, Huang PL. Diabetes Mellitus and the Metabolic Syndrome. MGH Cardiology Board Review 2014. [DOI: 10.1007/978-1-4471-4483-0_7] [Reference Citation Analysis]
262 Ammon HPT, Burchard A, Drexel H, Füchtenbusch M, Häring H, Hauner H, Joost H, Matthaei S, Merkel M, Müller-wieland D, Pfohl M, Roden M, Rustenbeck I, Säly C, Schatz H, Schifferdecker E, Schinner S, Schwarz P, Szendrödi J, Vonbank A, Wascher T, Zeyfang A. Typ-2-Diabetes. Diabetologie kompakt 2014. [DOI: 10.1007/978-3-642-41358-2_4] [Reference Citation Analysis]
263 Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, Defronzo R, Cefalu WT. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013;36:1779-88. [PMID: 23704680 DOI: 10.2337/dc13-0512] [Cited by in Crossref: 110] [Cited by in F6Publishing: 116] [Article Influence: 12.2] [Reference Citation Analysis]
264 Genuth SM. How does pioglitazone prevent progression of impaired glucose tolerance to diabetes? Diabetes 2013;62:3663-5. [PMID: 24158994 DOI: 10.2337/db13-1175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
265 Wentworth JM, Hensman T, Playfair J, Laurie C, Ritchie ME, Brown WA, Skinner S, Shaw JE, O'Brien PE. Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes. Diabetologia 2014;57:463-8. [PMID: 24310563 DOI: 10.1007/s00125-013-3129-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
266 Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068-1083. [PMID: 24315620 DOI: 10.1016/s0140-6736(13)62154-6] [Cited by in Crossref: 942] [Cited by in F6Publishing: 990] [Article Influence: 104.7] [Reference Citation Analysis]
267 Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36:1406-1412. [PMID: 23613600 DOI: 10.2337/dc12-2067] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
268 RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37:780-788. [PMID: 24194506 DOI: 10.2337/dc13-1879] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
269 Marini MA, Frontoni S, Succurro E, Arturi F, Fiorentino TV, Sciacqua A, Hribal ML, Perticone F, Sesti G. Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One 2013;8:e77440. [PMID: 24194886 DOI: 10.1371/journal.pone.0077440] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
270 Ransom T, Goldenberg R, Mikalachki A, Prebtani AP, Punthakee Z. Réduction du risque de diabète. Canadian Journal of Diabetes 2013;37:S377-S380. [DOI: 10.1016/j.jcjd.2013.07.033] [Reference Citation Analysis]
271 Meneilly GS, Knip A, Tessier D. Le diabète chez les personnes âgées. Canadian Journal of Diabetes 2013;37:S567-S574. [DOI: 10.1016/j.jcjd.2013.07.041] [Reference Citation Analysis]
272 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013;36:3607-3612. [PMID: 24062330 DOI: 10.2337/dc13-0520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
273 Herman WH. The economic costs of diabetes: is it time for a new treatment paradigm? Diabetes Care 2013;36:775-6. [PMID: 23520368 DOI: 10.2337/dc13-0270] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
274 Page KA, Reisman T. Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep 2013;13:252-60. [PMID: 23371283 DOI: 10.1007/s11892-013-0363-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
275 Khavandi K, Amer H, Ibrahim B, Brownrigg J. Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis. 2013;4:242-261. [PMID: 23997928 DOI: 10.1177/2040622313494986] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
276 Green JB. Diabetes trials: is an ounce of prevention enough? Expert Rev Endocrinol Metab 2013;8:419-21. [PMID: 30754187 DOI: 10.1586/17446651.2013.827382] [Reference Citation Analysis]
277 García de la Torre N, Durán A, Del Valle L, Fuentes M, Barca I, Martín P, Montañez C, Perez-Ferre N, Abad R, Sanz F, Galindo M, Rubio MA, Calle-Pascual AL. Early management of type 2 diabetes based on a SMBG strategy: the way to diabetes regression--the St Carlos study : a 3-year, prospective, randomized, clinic-based, interventional study with parallel groups. Acta Diabetol 2013;50:607-14. [PMID: 23532298 DOI: 10.1007/s00592-013-0467-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
278 Mannucci E, Monami M, Dicembrini I, Rotella C. The impossible return to the Garden of Eden: The ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2013;23:e35-e36. [DOI: 10.1016/j.numecd.2013.02.008] [Reference Citation Analysis]
279 Huisa BN, Roy G, Kawano J, Schrader R. Glycosylated hemoglobin for diagnosis of prediabetes in acute ischemic stroke patients. J Stroke Cerebrovasc Dis 2013;22:e564-7. [PMID: 23871698 DOI: 10.1016/j.jstrokecerebrovasdis.2013.06.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
280 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013;62:3920-6. [PMID: 23863810 DOI: 10.2337/db13-0265] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
281 Makrilakis K, Liatis S, Gilis-januszewska A, Schwarz P. Diabetes Prevention in Practice: Examples from the Real World. Prevention of Diabetes 2013. [DOI: 10.1002/9781118661321.ch8] [Reference Citation Analysis]
282 Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123:2764-72. [PMID: 23863634 DOI: 10.1172/JCI67227] [Cited by in Crossref: 556] [Cited by in F6Publishing: 577] [Article Influence: 61.8] [Reference Citation Analysis]
283 Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 2013;56:2153-63. [PMID: 23811853 DOI: 10.1007/s00125-013-2976-z] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 6.3] [Reference Citation Analysis]
284 Journal of Diabetes NEWS. Journal of Diabetes 2013;5:97-101. [DOI: 10.1111/1753-0407.12036] [Reference Citation Analysis]
285 Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM; GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013;36:2254-61. [PMID: 23690531 DOI: 10.2337/dc13-0356] [Cited by in Crossref: 183] [Cited by in F6Publishing: 190] [Article Influence: 20.3] [Reference Citation Analysis]
286 Gohlke H, Albus C, Bönner G, Darius H, Eckert S, Gohlke-bärwolf C, Gysan D, Hahmann H, Halle M, Hambrecht R, Mathes P, Predel H, Sauer † G, von Schacky C, Schuler G, Siegrist J, Thiery J, Tschöpe D, Völler H, Wirth A. Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Kardiologe 2013;7:141-156. [DOI: 10.1007/s12181-012-0468-x] [Reference Citation Analysis]
287 Genovese S, Passaro A, Brunetti P, Comaschi M, Cucinotta D, Egan CG, Chinea B, Bravi F, Di Pietro C; PRISMA study group. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. J Endocrinol Invest 2013;36:606-16. [PMID: 23511244 DOI: 10.3275/8895] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Roe ED, Pon NC, Hollander P, Raskin P. The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes. Diabetes Management 2013;3:145-160. [DOI: 10.2217/dmt.13.5] [Reference Citation Analysis]
289 Kitabchi AE, McDaniel KA, Wan JY, Tylavsky FA, Jacovino CA, Sands CW, Nyenwe EA, Stentz FB. Effects of high-protein versus high-carbohydrate diets on markers of β-cell function, oxidative stress, lipid peroxidation, proinflammatory cytokines, and adipokines in obese, premenopausal women without diabetes: a randomized controlled trial. Diabetes Care 2013;36:1919-25. [PMID: 23404297 DOI: 10.2337/dc12-1912] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 6.7] [Reference Citation Analysis]
290 Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17:R8. [PMID: 23327199 DOI: 10.1186/cc11932] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
291 Chu Y, Lund DD, Weiss RM, Brooks RM, Doshi H, Hajj GP, Sigmund CD, Heistad DD. Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013;33:523-32. [PMID: 23288158 DOI: 10.1161/ATVBAHA.112.300794] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
292 Kabadi UM. Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes. JDM 2013;03:129-133. [DOI: 10.4236/jdm.2013.33019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
293 Suvag S, Utzschneider KM, Kahn SE. Treatment with Thiazolidinediones. The Metabolic Syndrome 2013. [DOI: 10.1007/978-3-7091-1331-8_9] [Reference Citation Analysis]
294 Aquilante CL, Lam YF. The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management. Pharmacogenomics 2013. [DOI: 10.1016/b978-0-12-391918-2.00007-x] [Reference Citation Analysis]
295 Opie LH, Meier J. Metabolic syndrome, hyperglycemia, and type 2 diabetes. Drugs for the Heart 2013. [DOI: 10.1016/b978-1-4557-3322-4.00020-x] [Reference Citation Analysis]
296 Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology 2012;56:2172-9. [PMID: 22707355 DOI: 10.1002/hep.25887] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
297 Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:393-399. [PMID: 23175674 DOI: 10.1161/atvbaha.112.300346] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 8.4] [Reference Citation Analysis]
298 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
299 Freeman JS, Horton ES. What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms. American Journal of Therapeutics 2012;19:449-64. [DOI: 10.1097/mjt.0b013e31826fc5e5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
300 Lebovitz HE. Type 2 diabetes: the evolution of a disease. Diabetes & Vascular Disease 2012;12:290-298. [DOI: 10.1177/1474651412470289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
301 Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts. Pharmacogenet Genomics. 2012;22:484-497. [PMID: 22437669 DOI: 10.1097/fpc.0b013e328352a72e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
302 Choudhary N, Kalra S, Unnikrishnan AG, Ajish TP. Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16:33-43. [PMID: 22276251 DOI: 10.4103/2230-8210.91183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
303 Anagnostis P. Metabolic syndrome in the Mediterranean region: Current status. Indian J Endocrinol Metab 2012;16:72-80. [PMID: 22276255 DOI: 10.4103/2230-8210.91195] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
304 Lin SX, Berlin I, Younge R, Jin Z, Sibley CT, Schreiner P, Szklo M, Bertoni AG. Does elevated plasma triglyceride level independently predict impaired fasting glucose?: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2013;36:342-7. [PMID: 23033247 DOI: 10.2337/dc12-0355] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
305 Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res 2013;161:145-55. [PMID: 23022285 DOI: 10.1016/j.trsl.2012.08.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
306 Yu X, Chen P, Wang H, Zhu T. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients. Med Princ Pract 2013;22:156-60. [PMID: 22964975 DOI: 10.1159/000341770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
307 Insulin Resistance, Metabolic Syndrome, and Therapy. Metabolic Syndrome and Cardiovascular Disease 2012. [DOI: 10.1002/9781118480045.ch15] [Reference Citation Analysis]
308 Bacon S, Kyithar MP, Schmid J, Rizvi SR, Bonner C, Graf R, Prehn JH, Byrne MM. Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward. BMC Endocr Disord 2012;12:13. [PMID: 22808921 DOI: 10.1186/1472-6823-12-13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
309 Cao L, Li J, Wu H, Liu GJ, Dong BR, Lü Q. Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2012. [DOI: 10.1002/14651858.cd009989] [Reference Citation Analysis]
310 Green LW, Brancati FL, Albright A; Primary Prevention of Diabetes Working Group. Primary prevention of type 2 diabetes: integrative public health and primary care opportunities, challenges and strategies. Fam Pract 2012;29 Suppl 1:i13-23. [PMID: 22399542 DOI: 10.1093/fampra/cmr126] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
311 Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8:639-649. [PMID: 22751341 DOI: 10.1038/nrendo.2012.96] [Cited by in Crossref: 344] [Cited by in F6Publishing: 359] [Article Influence: 34.4] [Reference Citation Analysis]
312 Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol 2012;11:79. [PMID: 22748110 DOI: 10.1186/1475-2840-11-79] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
313 Færch K, Bergman B, Perreault L. Does insulin resistance drive the association between hyperglycemia and cardiovascular risk? PLoS One 2012;7:e39260. [PMID: 22720085 DOI: 10.1371/journal.pone.0039260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
314 Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-51. [PMID: 22683134 DOI: 10.1016/S0140-6736(12)60525-X] [Cited by in Crossref: 288] [Cited by in F6Publishing: 313] [Article Influence: 28.8] [Reference Citation Analysis]
315 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
316 Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC; GERP ALS Study Group. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 2012;7:e37885. [PMID: 22715372 DOI: 10.1371/journal.pone.0037885] [Cited by in Crossref: 103] [Cited by in F6Publishing: 110] [Article Influence: 10.3] [Reference Citation Analysis]
317 Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012;11:64. [PMID: 22681705 DOI: 10.1186/1475-2840-11-64] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
318 Huang JV, Greyson CR, Schwartz GG. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res 2012;53:1738-54. [PMID: 22685322 DOI: 10.1194/jlr.R024505] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
319 Carnevale Schianca GP, Sola D, Rossi L, Fra GP, Bartoli E. The management of type 2 diabetic patients with hypoglycemic agents. ISRN Endocrinol 2012;2012:601380. [PMID: 22577575 DOI: 10.5402/2012/601380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Tsang MW. The management of type 2 diabetic patients with hypoglycaemic agents. ISRN Endocrinol 2012;2012:478120. [PMID: 22645689 DOI: 10.5402/2012/478120] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
321 Norris AW, Sigmund CD. A second chance for a PPARγ targeted therapy? Circ Res 2012;110:8-11. [PMID: 22223206 DOI: 10.1161/RES.0b013e3182435d88] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
322 Albert DA, Ward A, Allweiss P, Graves DT, Knowler WC, Kunzel C, Leibel RL, Novak KF, Oates TW, Papapanou PN. Diabetes and oral disease: implications for health professionals. Ann N Y Acad Sci. 2012;1255:1-15. [PMID: 22409777 DOI: 10.1111/j.1749-6632.2011.06460.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
323 R. M, L. L, R. H, B. P, R. P. Nanosciences, Diabetes and the Patient. Nanotechnology and Nanomedicine in Diabetes 2012. [DOI: 10.1201/b11775-25] [Reference Citation Analysis]
324 Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M. Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. PLoS One 2012;7:e31516. [PMID: 22412837 DOI: 10.1371/journal.pone.0031516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
325 Marini MA, Succurro E, Frontoni S, Mastroianni S, Arturi F, Sciacqua A, Lauro R, Hribal ML, Perticone F, Sesti G. Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 2012;35:868-72. [PMID: 22357182 DOI: 10.2337/dc11-2181] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
326 Mazza AD, Pratley RE, Smith SR. Beta-cell preservation…Is weight loss the answer? Rev Diabet Stud 2011;8:446-53. [PMID: 22580726 DOI: 10.1900/RDS.2011.8.446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
327 Buchanan TA, Page KA. Approach to the patient with gestational diabetes after delivery. J Clin Endocrinol Metab 2011;96:3592-8. [PMID: 22143829 DOI: 10.1210/jc.2011-1515] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
328 Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012;167:40-6. [PMID: 22132883 DOI: 10.1111/j.1365-2249.2011.04501.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
329 Schwarz PE, Greaves CJ, Lindström J, Yates T, Davies MJ. Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:363-73. [PMID: 22249519 DOI: 10.1038/nrendo.2011.232] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 8.8] [Reference Citation Analysis]
330 Karam JG, Mcfarlane SI. Prevention of Type 2 Diabetes: Evidence from Clinical Trials. Diabetes and Hypertension 2012. [DOI: 10.1007/978-1-60327-357-2_12] [Reference Citation Analysis]
331 Marment SKM, Semark AJ, Kruger PS. Glitazones: Could They Have a Rosy Future in Critical Care? Annual Update in Intensive Care and Emergency Medicine 2012 2012. [DOI: 10.1007/978-3-642-25716-2_14] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
332 Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 2012;20:364-70. [PMID: 22076596 DOI: 10.1038/oby.2011.337] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 7.6] [Reference Citation Analysis]
333 Kalra S, Malik S, John M. Gestational diabetes mellitus: A window of opportunity. Indian J Endocrinol Metab 2011;15:149-51. [PMID: 21897889 DOI: 10.4103/2230-8210.83395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
334 Garber AJ. Incretin therapy--present and future. Rev Diabet Stud. 2011;8:307-322. [PMID: 22262069 DOI: 10.1900/rds.2011.8.307] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
335 Kahn SE, Utzschneider KM. What's next for diabetes prevention? Diabetes Care 2011;34:1678-80. [PMID: 21709302 DOI: 10.2337/dc11-0694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
336 Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE. Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS Med Chem Lett 2011;3:39-42. [PMID: 22282722 DOI: 10.1021/ml200196p] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 5.5] [Reference Citation Analysis]
337 Knowler WC. Prevention of type 2 diabetes: comment on "Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels". Arch Intern Med 2011;171:1361-2. [PMID: 21824949 DOI: 10.1001/archinternmed.2011.367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
338 Tjota MY, Kozak BM, Chang EM, Wu VL, Close KL. Journal of Diabetes NEWS: Diabetes News. Journal of Diabetes 2011;3:174-81. [DOI: 10.1111/j.1753-0407.2011.00140.x] [Reference Citation Analysis]
339 Hanefeld M, Schatz U, Schaper F. Treatments for the Metabolic Syndrome. The Metabolic Syndrome 2011. [DOI: 10.1002/9781444347319.ch18] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, Smith RJ, Smith SR. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96:1654-1663. [PMID: 21602457 DOI: 10.1210/jc.2011-0585] [Cited by in Crossref: 284] [Cited by in F6Publishing: 299] [Article Influence: 25.8] [Reference Citation Analysis]
341 DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34 Suppl 2:S202-9. [PMID: 21525456 DOI: 10.2337/dc11-s221] [Cited by in Crossref: 94] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
342 Chiasson J, Bernard S. Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management 2011;1:423-438. [DOI: 10.2217/dmt.11.28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
343 Pfützner A, Hanefeld M, Dekordi LA, Müller J, Kleine I, Fuchs W, Forst T. Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. J Diabetes Sci Technol 2011;5:989-98. [PMID: 21880242 DOI: 10.1177/193229681100500422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
344 Tripathy D, Defronzo RA. Can we prevent diabetes with a single pill? Diabetes Management 2011;1:355-358. [DOI: 10.2217/dmt.11.35] [Reference Citation Analysis]
345 Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, Smith RJ, Smith SR; Endocrine Society., American Diabetes Association., European Association for the Study of Diabetes. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 2011;34:1424-30. [PMID: 21602431 DOI: 10.2337/dc11-0447] [Cited by in Crossref: 159] [Cited by in F6Publishing: 173] [Article Influence: 14.5] [Reference Citation Analysis]
346 Sørensen TI. Obesity defined as excess storage of inert triglycerides--do we need a paradigm shift? Obes Facts 2011;4:91-4. [PMID: 21577014 DOI: 10.1159/000328198] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
347 Aasheim E. Pioglitazon ved forebygging av type 2-diabetes. Tidsskriftet 2011;131:1176-1176. [DOI: 10.4045/tidsskr.11.0497] [Reference Citation Analysis]